Dec 13. 2022
KaliVir Immunotherapeutics Establishes Clinical and Scientific Advisory Boards
Nov 10. 2022
KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting
Nov 1. 2022
KaliVir Appoints Industry Veteran Adina Pelusio as Senior Vice President of Clinical Operations to Lead Clinical Development Pipeline
Oct 24. 2022
KaliVir Immunotherapeutics to Present at 14th International Oncolytic Virotherapy Conference (IOVC)
Oct 5. 2022
KaliVir Immunotherapeutics to Present Data on its Novel Pre-Clinical Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) Annual Meeting
May 23. 2022
KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
Mar 16. 2022
KaliVir Immunotherapeutics Closes Series A Financing
Nov 4. 2021
KaliVir Immunotherapeutics Strengthens Intellectual Property Position Through Issuance of Two U.S. Patents.
December 7. 2020
KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus.
2020
How Stephen Thorne and Helena Chaye are blending their talents to create Breakthrough cancer fighting therapies
June 17. 2021
KaliVir Immunotherapeutics appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
